Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

Abstract	Rivastigmine has been shown to improve cognition in patients with Parkinson's disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 to 12 mg/d rivastigmine capsules and 179 to placebo. Patients with PDD receiving rivastigmine improved versus placebo on items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language (P < .05), with standardized mean differences ranging from 0.04 to 0.30. Rivastigmine also showed significant effects versus placebo on all domains: memory, language, and praxis. The ADAS-cog is sensitive to broad cognitive changes in PDD. Overall, rivastigmine was associated with improvements on individual cognitive items and general cognitive domains.
Authors	Frederick A Schmitt, Dag Aarsland, Kolbjørn S Brønnick, Xiangyi Meng, Sibel Tekin, Jason T Olin
Journal	American journal of Alzheimer's disease and other dementias (Am J Alzheimers Dis Other Demen) Vol. 25 Issue 5 Pg. 407-13 (Aug 2010) ISSN: 1938-2731 [Electronic] United States
PMID	20392860 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Neuroprotective Agents Phenylcarbamates Rivastigmine
Topics	Cognition (drug effects) Cognition Disorders (diagnosis, drug therapy) Dementia (diagnosis, drug therapy) Humans Neuroprotective Agents (administration & dosage) Neuropsychological Tests Parkinson Disease (diagnosis, drug therapy) Phenylcarbamates (administration & dosage) Randomized Controlled Trials as Topic Retrospective Studies Rivastigmine Severity of Illness Index Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!